 |
|
Comprehensive treatment of extensively drug-resistant TB works, study finds
August 07, 2008The death sentence that too often accompanies a diagnosis of extensively drug-resistant tuberculosis (XDR-TB) can be commuted if an individualized outpatient therapy program is followed - even in countries with limited resources and a heavy burden of TB.
A study conducted in Peru between 1999 and 2002 shows that more than 60 percent of XDR-TB patients not co-infected with HIV were cured after receiving the bulk of their personalized treatment at home or in community-based settings. The paper appears in the August 7, 2008 issue of The New England Journal of Medicine.
"It's essential that the world know that XDR-TB is not a death sentence," says lead author Carole Mitnick, instructor in the Department of Global Health and Social Medicine at Harvard Medical School (HMS). "As or even more importantly, our study shows that effective treatment does not require hospitalization or indefinite confinement of patients."
In some parts of the world, however, patients with XDR-TB and other drug-resistant forms of the disease are confined against their will in TB hospitals that resemble prisons, Mitnick adds.
Researchers from HMS, Brigham and Women's Hospital, Partners In Health, Harvard School of Public Health, and the Massachusetts State Laboratory Institute, along with Lima, Peru-based organizations Socios en Salud, the Peruvian Ministry of Health, and Hospital Nacional Sergio E. Bernales, had already demonstrated that aggressive, outpatient treatment could cure multi-drug resistant tuberculosis (MDR-TB), which is resistant to two first-line anti-TB drugs. That pilot program has been adopted as a national endeavor by the Peruvian government.
A similar protocol was used for the recent study of XDR-TB, which is caused by TB bacteria that are resistant not only to the same first-line anti-TB drugs, but also to the two most important second-line drug classes.
A total of 810 patients with unsuccessfully treated tuberculosis were referred for free individualized drug treatment and additional services as needed, including surgery, adverse-event management, and nutritional and psychological support. Sputum culture and drug-susceptibility testing results, performed at the Massachusetts State Laboratory Institute in Boston, were available for 651 patients. Based on susceptibility results for 12 anti-TB drugs, clinicians developed regimens that included five or more drugs to which the infecting strains were likely to respond. Forty-eight patients had XDR-TB; 603 had MDR-TB. None of the XDR-TB patients were co-infected with the HIV virus.
At the end of treatment, 60.4 percent in the XDR-TB group were cured; 66.3 percent with MDR-TB were cured. The outcomes among XDR-TB patients were better than most reported from hospital settings in Europe, the U.S., and Korea, Mitnick says.
Frequent contact with healthcare workers afforded many benefits and was an important element of success. Daily, supervised treatment was delivered in patient homes and at community health centers. The community health workers ensured a high level of treatment adherence and promptly detected circumstances requiring additional attention, including adverse events. Psycho-social needs were also assessed continuously and addressed through a range of interventions.
"It's important for people to understand that this ambulatory form of treatment exists, is successful, and can be widely implemented in resource-poor settings," Mitnick says.
Community-based interventions also protect hospital patients and staff from transmission of TB and allow TB patients to remain with their families during this protracted treatment. If hospitals have to accommodate only those with serious medical needs, this intervention can be implemented widely, and earlier in the disease course.
The benefits would be profound, Mitnick says. In addition to reduced morbidity and mortality among patients, an epidemiologic impact could be expected: a decrease in the incidence of resistant TB has been reported only in places where universal screening and treatment for DR-TB are offered at first TB diagnosis.
"DR-TB is everywhere in the world it's been looked for and it's not going away without additional resources," Mitnick says. According to a notice issued by the World Health Organization this year, ever since it was first described in 2006, XDR-TB has been reported in 49 countries, including the United States. Approximately 1.5 million people are estimated to have MDR-TB, "but no one really knows how many have XDR-TB." Expanded community-based delivery of improved treatment is essential to stem this epidemic.
Harvard Medical School
In some parts of the world, however, patients with XDR-TB and other drug-resistant forms of the disease are confined against their will in TB hospitals that resemble prisons, Mitnick adds.
Researchers from HMS, Brigham and Women's Hospital, Partners In Health, Harvard School of Public Health, and the Massachusetts State Laboratory Institute, along with Lima, Peru-based organizations Socios en Salud, the Peruvian Ministry of Health, and Hospital Nacional Sergio E. Bernales, had already demonstrated that aggressive, outpatient treatment could cure multi-drug resistant tuberculosis (MDR-TB), which is resistant to two first-line anti-TB drugs. That pilot program has been adopted as a national endeavor by the Peruvian government.
A similar protocol was used for the recent study of XDR-TB, which is caused by TB bacteria that are resistant not only to the same first-line anti-TB drugs, but also to the two most important second-line drug classes.
A total of 810 patients with unsuccessfully treated tuberculosis were referred for free individualized drug treatment and additional services as needed, including surgery, adverse-event management, and nutritional and psychological support. Sputum culture and drug-susceptibility testing results, performed at the Massachusetts State Laboratory Institute in Boston, were available for 651 patients. Based on susceptibility results for 12 anti-TB drugs, clinicians developed regimens that included five or more drugs to which the infecting strains were likely to respond. Forty-eight patients had XDR-TB; 603 had MDR-TB. None of the XDR-TB patients were co-infected with the HIV virus.
At the end of treatment, 60.4 percent in the XDR-TB group were cured; 66.3 percent with MDR-TB were cured. The outcomes among XDR-TB patients were better than most reported from hospital settings in Europe, the U.S., and Korea, Mitnick says.
Frequent contact with healthcare workers afforded many benefits and was an important element of success. Daily, supervised treatment was delivered in patient homes and at community health centers. The community health workers ensured a high level of treatment adherence and promptly detected circumstances requiring additional attention, including adverse events. Psycho-social needs were also assessed continuously and addressed through a range of interventions.
"It's important for people to understand that this ambulatory form of treatment exists, is successful, and can be widely implemented in resource-poor settings," Mitnick says.
Community-based interventions also protect hospital patients and staff from transmission of TB and allow TB patients to remain with their families during this protracted treatment. If hospitals have to accommodate only those with serious medical needs, this intervention can be implemented widely, and earlier in the disease course.
The benefits would be profound, Mitnick says. In addition to reduced morbidity and mortality among patients, an epidemiologic impact could be expected: a decrease in the incidence of resistant TB has been reported only in places where universal screening and treatment for DR-TB are offered at first TB diagnosis.
"DR-TB is everywhere in the world it's been looked for and it's not going away without additional resources," Mitnick says. According to a notice issued by the World Health Organization this year, ever since it was first described in 2006, XDR-TB has been reported in 49 countries, including the United States. Approximately 1.5 million people are estimated to have MDR-TB, "but no one really knows how many have XDR-TB." Expanded community-based delivery of improved treatment is essential to stem this epidemic.
Harvard Medical School
Tuberculosis Current Events and Tuberculosis News RSSStopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
First trachea transplant without immunosuppression
After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis.
Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System
A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases.
XDR-TB: Deadlier and more mysterious than ever
New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Parasites that live inside cells use loophole to thwart immune system
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide.
Persistent bacterial infection exploits killing machinery of immune cells
A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.
Health Care Barriers for Undocumented Immigrants: Raising Tuberculosis Risk?
A new study raises the question, do barriers to health care for undocumented immigrants increase the public health risk of tuberculosis? The study, published in the November 15, 2008 issue of Clinical Infectious Diseases and now available online, suggests that undocumented immigrants with tuberculosis have symptoms longer before seeking care than documented immigrants or U.S.-born patients, resulting in more severe symptoms and more opportunities for transmission.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
New TB test reveals patients at risk, says study
A recently introduced blood test can reveal which patients may develop active tuberculosis (TB) much more precisely than the 100-year old TB skin test, according to a new study published today in the journal Annals of Internal Medicine.
More Tuberculosis Current Events and Tuberculosis News Articles
 | Timebomb : The Global Epidemic of Multi-Drug Resistant Tuberculosis by Lee Reichman, Janice Hopkins Tanne "A chilling account of... the global resurgence of this disease..."--The New York Times "Tuberculosis--a nineteenth century disease--has come back with a vengeance... Timebomb is the extraordinary story of courage and cowardice in confronting the global TB epidemic."--Donna E. Shalala, former Secretary of Health and Human Services, President of the University of... |
 | The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of... |
 | Tuberculosis (Twenty-First Century Medical Library) by Diane Yancey One of the deadliest diseases healthcare workers fight today, tuberculosis (often called TB) infects the lungs of one-third of the world's population and kills about 2 million people a year. While scientific breakthroughs brought this bacterial disease under control during the 1960s to the 1980s, it was never completely eliminated. In the early 1990s, TB came back as a serious global threat. Not... |
 | Tuberculosis (TUBERCULOSIS ( ROM)) This comprehensive clinical reference is edited by experts from the NYU-Bellevue Chest Service, which through its influence in tuberculosis care and education has been an integral part of the formation of the entire specialty of pulmonary medicine. The book draws on this extensive experience to present an authoritative account of the history, epidemiology, microbiology, immunology, clinical... |
 | Clinical Tuberculosis (A Hodder Arnold Publication) by Peter D Davies, Peeter Barnes, Stephen B Gordon Clinical Tuberculosis remains an indispensable resource for respiratory physicians, infectious disease specialists, public health workers and other individuals involved in the management and control of tuberculosis worldwide. This established reference is a comprehensive accoutn of tuberculosis, providing up-to-date and authoritative information on all aspects of the disease. It gives practical... |
 | Diagnostics for tuberculosis: Global demand and market potential by World Health Organization's Special Programme for Tropical Diseases Research (TDR) In this report the World Health Organization's Special Programme for Tropical Diseases Research (TDR), in collaboration with the Foundation for Innovative New Diagnostics (FIND), has compiled existing epidemiological data and generated a wealth of new data on the availability of TB laboratory services, variations in physician diagnostic practices, workloads of national laboratory networks, and... |
| The Modern Epidemic: A History of Tuberculosis in Japan (Harvard East Asian Monographs) by William Johnston Through a historical and comparative analysis of modern Japan's epidemic of tuberculosis, William Johnston illuminates a major but relatively unexamined facet of Japanese social and cultural history. He utilizes a broad range of sources, including medical journals and monographs, archaeological evidence, literary works, ethnographic data, and legal and government documents to reveal how this and... | |
| White Death: A History of Tuberculosis by Thomas Dormandy The victims of tuberculosis (TB; usually known as consumption) included not only Keats, the Brontes, Chopin & Chekhov but members of almost every family. It was a killer on a huge scale. This highly praised book provides a history of tuberculosis as a whole. Thomas Dormandy's account of the search for a cure is complemented by a description of the disease's complex natural history; & by portraits... | |
 | Mycobacterium Tuberculosis Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Leading investigators with extensive practical knowledge and experience describe their best methods for studying the tuberculosis pathogen. Packed with step-by-step instructions to ensure successful results, these methods range from basic handling techniques to the application of functional genomics. Highlights include methods for the basic safety and culture of M. tuberculosis, fractionation of... |
 | Handbook of Tuberculosis Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. ... |
| © 2008 BrightSurf.com |